CORRECTED: 9amHealth Selects Smart Meter for Employer Weight Management Programs with Cellular Scale Integration
SMART METER SELECTED BY 9AMHEALTH FOR MAJOR EMPLOYER WEIGHT MANAGEMENT PROGRAMS USING CELLULAR WEIGHT SCALE Smart Meter, a pioneer in cellular-enabled weight scale technology, today announced a strategic supply agreement with 9amHealth, a leading provider of comprehensive weight management and…
SynergenX Launches Mobile App to Simplify Hormone Health Management
SynergenX, a national leader revolutionizing hormone therapy, TRT, weight loss, and wellness services, is proud to announce the launch of the SynergenX App, now available for free download on the Apple App Store and Google Play. This user-friendly digital platform is designed to…
KalVista Reports FDA Delay on Sebetralstat NDA for Hereditary Angioedema Due to Resource Constraints
KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that the U.S. Food and Drug Administration (FDA) has notified the Company that it will not meet the PDUFA goal date for the New Drug Application (NDA) for sebetralstat, the Company’s investigational oral…
Cerus Corporation Celebrates World Blood Donor Day 2025
Cerus Corporation (Nasdaq: CERS) is proud to announce its celebration of World Blood Donor Day 2025. In 2005, the World Health Assembly designated June 14th as World Blood Donor Day to recognize and thank blood donors across the world for…
Valar Labs’ CHAI Biomarkers Validated in New Study in European Urology for Predicting Outcomes of High Grade Ta Bladder Cancer
Valar Labs, a pioneer in AI-powered diagnostics for oncology, announced the publication of its latest research in European Urology, the highest-impact journal in the field of urology. The peer-reviewed study highlights the performance and clinical impact of Valar Labs’ Vesta platform…
Cybin Shares Corporate Update and Positive Regulatory Progress for Psychedelic Therapies
Cybin Inc. (NYSE American:CYBN) (Cboe Canada CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today provided a corporate update. “It is especially gratifying that at a…
Astria Therapeutics Shares Promising Early Data from Navenibart Trial in Hereditary Angioedema at EAACI Congress
a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced positive initial results from the target enrollment group in the ongoing ALPHA-SOLAR long-term open-label trial evaluating navenibart (STAR-0215), a monoclonal antibody inhibitor of plasma kallikrein,…
Zai Lab Unveils Preclinical Data on ZL-1503 for Atopic Dermatitis at EAACI 2025
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) announced new data from its preclinical study of ZL-1503, the Company’s promising IL-13/IL-31R bispecific antibody, demonstrating its ability to simultaneously suppress the inflammatory and pruritogenic (itch-causing) pathways in atopic dermatitis (AD). The findings,…
FDA Approves KEYTRUDA® for PD-L1+ Head & Neck Cancer in Neoadjuvant and Adjuvant Settings
FDA Approves KEYTRUDA® for PD-L1+ Head & Neck Cancer in Neoadjuvant and Adjuvant Settings Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA® (pembrolizumab), Merck’s…
Ethris and Thermo Fisher Partner to Expand Access to mRNA Technology Platforms
Ethris GmbH, a clinical-stage biotechnology company pioneering next-generation RNA therapeutics and vaccines, today announced a strategic collaboration with Thermo Fisher Scientific, the world leader in serving science, to provide a fully integrated mRNA solution to biopharmaceutical developers. The collaboration brings…
City of Hope Unveils Tumor Cell Map to Advance Personalized Brain Cancer Therapy
City of Hope®, one of the largest and most advanced cancer research and treatment organizations in the U.S. with its National Medical Center named top 5 in the nation for cancer by U.S. News & World Report, co-led the first…
MaaT Pharma Reports Positive Xervyteg® Data at EHA, Confirming ARES Study Results in GvHD
MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival for patients with cancer through immune modulation, today announced that Professor Mohamad Mohty, Professor of Hematology…